| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) |
| Formulation | 92 micrograms/22 micrograms and 184 micrograms/22 micrograms inhalation powder |
| Reference number | 3489 |
| Indication | Regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist |
| Company | GlaxoSmithKline |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/03/2018 |